On May 5, 2025, the Belgian Health Care Knowledge Centre (KCE) opened its annual call for topic proposals for the 2026 research program, which includes Clinical Guidelines, Health Technology Assessments, and Health Services Research. Interested stakeholders can submit the proposals by June 30, 2025.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Wang et al. conducted a survey and multi-stakeholder workshop to assess the readiness and strategic approaches of pharmaceutical companies regarding the Joint Clinical Assessment (JCA) under the new European HTA Regulation. Thirteen companies took part, reporting moderate preparedness for the JCA process (with readiness scores of 6–7 out of 10), but expressing concerns about uncertain timelines and challenges in integrating JCA outcomes into national processes. To support effective JCA implementation in national HTA decisions, the authors recommend creating a product-based scorecard for submission quality, increasing member state training, and promoting ongoing dialogue among key stakeholders.

In May 2025, the evaluation phase of the “New Methods” framework was completed for three technologies: leadless pacemaker for cardiac arrhythmias, MR-guided focused ultrasound for essential tremor, and Electrical Field Therapy for glioblastoma treatment. As the recommendations from HTA are now available, the Decision Forum needs to make coverage decisions for these technologies.

MTRC, a leading boutique Med Tech market access consultancy in Europe, is looking for a Senior Evidence Synthesis Specialist.

MTRC, a leading boutique Med Tech market access consultancy in Europe, is looking for a Director of Evidence Synthesis to lead our growing evidence synthesis function.

MTRC is pleased to announce the release of its latest White Paper: "Transitional Coverage of Innovative Medical Devices in France (pre-LPPR)". This White Paper is designed for medical device manufacturers, market access experts, and health policy leaders who are shaping strategies for early adoption in the French market.

MTRC is pleased to announce the release of its latest White Paper: "Evidence requirements for the creation of IVD reimbursement (NABM) codes in France". This document sheds light on the broader evidence requirements and decision-making framework used by HAS, offering diagnostics manufacturers critical insights into the expectations and potential challenges of securing NABM reimbursement.

In April 2025, the French National Authority for Health (HAS) opened the application period for including medical procedures and in-vitro diagnostic tests in its 2026 evaluation working program. The application deadline is July 8, 2025.

On May 15, 2025, the Swiss Federal Statistics Office announced that the 2025 application process for the further development of the Swiss Classification of Surgical Procedures (CHOP), which would result in changes in the CHOP 2027, is cancelled due to the federal government's cost-saving measures. The CHOP and Coding Manual for 2027 will only be developed based on deferred applications.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Mastronardi et al. evaluated the implementation of a recycling program in operating rooms at a single Italian center to reduce environmental impact and costs. Conducted from June 2023 to April 2024, the study demonstrated that recycling 21.8% of operating room waste led to an 11.6% reduction in CO2 emissions and 13.5% cost savings in waste disposal. These results highlight the feasibility and benefits of structured recycling initiatives in surgical settings.

In May 2025, the Dutch Healthcare Institute (ZIN) published the Trendwatch Report on Healthcare Innovations in Specialist Medical Care, identifying 316 MedTech innovations across 11 clusters, with AI-driven diagnostics, predictive models, and image-guided therapy predicted to have the highest impact in the medical specialist care, while also highlighting significant risks associated with assistive robotics and wearable monitoring technologies for inclusion in basic health insurance.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of the 19th of May, we plan to work on 17 projects. Review the complete list of planned activities in this post.